Liraglutide
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
Novo Nordisk · Phase 3 · Status n/r · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
Not shown
- Liraglutide: endpoint not reported
- placebo: endpoint not reported